By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Five years after the Food and Drug Administration (FDA) first approved the use of Gilead’s HIV/AIDS treatment medication, Truvada (tenofovir/emtricitabine), for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition, a new article in the respected scientific journal ‘AIDS’ explores the U.S. Centers for Disease Control and Prevention’s (CDC) role in roll out of PrEP and asks the question: “Were We Prepared for PrEP?” The article, “Were We Prepared for PrEP? Five Years of Implementation,” was co-authored by Michael Weinstein, AHF President; Dr. Otto Yang, MD, ScD, Scientific Director for AHF and Adam Carl Cohen, PhD, MPH, AHF’s Director of Advocacy and Policy Research, and published as a ‘Viewpoint’ article in the October 4, 2017 edition of ‘AIDS,’ an official journal of the International AIDS Society (IAS).
The paper noted that AHF, “...voiced concerns that PrEP would be difficult to implement because of healthcare …
(2017-10-28), ‘AIDS’ Journal Article Asks: ‘Were We Prepared for PrEP?’, Obesity, Fitness & Wellness Week , 341, ISSN: 1532-4664, BUTTER® ID: 014540398